Adaptive Biotechnologies Corp (ADPT) stock
Close on Nov 12, 2026Market cap $4.70BP/E –Yield –
Adaptive Biotechnologies Corp grew revenue 17.9% to $298.01M over the twelve months to Sep 30, 2026. Free cash flow was -$8.82M. At the latest close the market valued the company at $4.70B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $4.70B
- P/E ratio
- –
- Price to sales
- 15.79
- Price to book
- 26.70
- Dividend yield
- –
- Free cash flow yield
- -0.19%
Fundamentals
- Revenue
- $298.01M
- Net income
- -$70.52M
- EPS, diluted
- -$0.45
- Free cash flow
- -$8.82M
- Book value per share
- $0.94
- Diluted shares
- 187M
Trading
- Next earnings
- Feb 4, 2027 (estimated, after the close)
- Previous close
- $29.94
- Open
- $29.20
- Day's range
- $28.59 – $29.78
- Volume
- 1,920,480
- Average volume (20 days)
- 2,197,728
- Index membership
- Russell 2000 (since Jun 2022), Russell 3000
- Beta (5 years)
- 1.79
- 52-week range
- $12.00 – $32.21
- RSI (14 days)
- 62.1
- Volatility (1 year)
- 66.6%
- Relative volume
- 1.14×
- WACC
- 13.8%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ADPT | S&P 500 | Difference | ADPT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +15.3% | -2.7% | +18.0 pts | ||
| 3 months | +16.8% | -1.7% | +18.5 pts | ||
| Year to date | +81.5% | +11.9% | +69.6 pts | ||
| 1 year | +103.3% | +12.0% | +91.3 pts | ||
| 3 years | +739.9% | +78.2% | +661.7 pts | +103.3% | +21.2% |
| 5 years | -11.2% | +73.2% | −84.5 pts | -2.4% | +11.6% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Adaptive Biotechnologies filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- News
- News
About Adaptive Biotechnologies
Biological Products, (No Diagnostic Substances)
Adaptive Biotechnologies Corporation operates an immune medicine platform that decodes the adaptive immune system to diagnose and treat diseases. The company is organized into two primary segments: the Minimal Residual Disease (MRD) business and the Immune Medicine (IM) business. In its MRD division, the company provides the clonoSEQ diagnostic test to measure residual disease burden in lymphoid malignancies, serving clinicians in healthcare settings and biopharmaceutical companies conducting clinical drug development trials. The IM business sequences, maps, and characterizes immune receptors, offering solutions such as immunosequencing services, data licensing, predictive models, and target discovery services to academic and biopharmaceutical partners.
Company profile, executives and historyAdaptive Biotechnologies stock: common questions
What is Adaptive Biotechnologies's stock price?
ADPT closed at $29.48 on Nov 12, 2026, down 1.54% on the day. Over the past 52 weeks it traded between $12.00 and $32.21.
What is Adaptive Biotechnologies's market cap?
Adaptive Biotechnologies was worth $4.70B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ADPT's P/E ratio?
Adaptive Biotechnologies lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.45), so it has no meaningful P/E ratio.
How much revenue does Adaptive Biotechnologies make?
Adaptive Biotechnologies reported revenue of $298.01M for the twelve months to Sep 30, 2026, up 17.9% from a year earlier.
Does Adaptive Biotechnologies pay a dividend?
No. Adaptive Biotechnologies has not paid a cash dividend over the last twelve months.
When does Adaptive Biotechnologies report earnings next?
Adaptive Biotechnologies is expected to report Q4 FY2026 results on Feb 4, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ADPT stock performed over the past year?
Including dividends, ADPT returned +103.3% over the past year, against +12.0% for the S&P 500.
How many ADPT shares are sold short?
11M shares were sold short at the latest FINRA report, 9.31% of the float, or 6.1 days of average trading volume.
Who are Adaptive Biotechnologies's competitors?
Companies most similar to Adaptive Biotechnologies by business, industry and size include IMCR, VIR, IBRX, IOVA, AGEN.
See a number that looks wrong?